Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Artigo em Inglês | MEDLINE | ID: mdl-30167108

RESUMO

Background: Colonization with multidrug-resistant (MDR) bacteria is a major risk factor for developing subsequent MDR infections. Methods: We performed a prospective surveillance study in hospitalized patients at Siriraj Hospital. Nasal cavity, throat, inguinal area and rectal swabs were obtained within the first 48-h after admission, on day-5 after hospitalization and then every 7 days until discharge. Target bacteria included extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL), carbapenem-resistant-P.aeruginosa (CR-PA), carbapenem-resistant-A.baumannii (CR-AB) and methicillin-resistant S.aureus (MRSA). Results: From January 2013-December 2014, 487 patients were enrolled. The baseline prevalence of colonization by ESBL, CR-PA, CR-AB and MRSA at any site was 52.2%, 6.8%, 4.7% and 7.2%, respectively. After 3-week of hospitalization, the prevalence of colonization by ESBL, CR-PA, CR-AB and MRSA increased to 71.7%, 47.2%, 18.9% and 18.9%, respectively. Multivariable analysis revealed that diabetes mellitus and recent cephalosporin exposure were the independent risk factors for baseline colonization by ESBL. The independent risk factors for CR-AB and/or CR-PA colonization were cerebrovascular diseases, previous hospitalization, transfer from another hospital/a LTCF and previous nasogastric tube use, whereas those for MRSA colonization were previous fluoroquinolone exposure and previous nasogastric tube use. Conclusions: The baseline prevalence of colonization by ESBL was relatively high, whereas the baseline prevalence of colonization by CR-PA, CR-AB and MRSA was comparable to previous studies. There was an increasing trend in MDR bacteria colonization after hospitalization.


Assuntos
Bactérias/efeitos dos fármacos , Infecções Bacterianas/microbiologia , Farmacorresistência Bacteriana Múltipla , Adulto , Idoso , Antibacterianos/uso terapêutico , Bactérias/classificação , Bactérias/genética , Bactérias/crescimento & desenvolvimento , Infecções Bacterianas/tratamento farmacológico , Infecções Bacterianas/terapia , Monitoramento Epidemiológico , Feminino , Hospitalização , Hospitais Universitários/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Tailândia/epidemiologia
2.
J Med Assoc Thai ; 97(12): 1254-8, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25764631

RESUMO

OBJECTIVE: To determine in vitro activity of polymyxin B against carbapenem-resistant Acinetobacter baumannii. MATERIAL AND METHOD: The activity of polymyxin B was determined against 217 strains of carbapenem-resistant A. baumannii collected from different patients by standard agar dilution method and disk diffusion test using polymyxin B disk (300 units). The control strains were E. coli ATCC 25922 and P. aeruginosa ATCC 27853. RESULTS: The MIC values and inhibition zone diameters of polymyxin B against the quality control bacteria were within the acceptable range. The MIC50 and MIC90 values of polymyxin B against 217 strains of carbapenem-resistant A. baumannii were 0.5 and 1 mg/l, respectively. If the susceptible MIC breakpoint of polymyxin B was ≤ 2 mg/l, 98.2% of carbapenem-resistant A. baumannii strains were susceptible to polymyxin B. If the susceptible MIC breakpoint of polymyxin B was ≤ 2 mg/l, the sensitivity and the specificity ofthe inhibition zone diameter of > 12 mm were 100% and 75%, respectively. The aforementioned diagnostic parameters gave positive predictive value of 99.5% and negative predictive value of 100% for predicting susceptibility of carbapenem-resistant A. baumannii to polymyxin B by disk diffusion test. CONCLUSION: Polymyxin B was very active against carbapenem-resistant A. baumannii. The inhibition zone diameters of >12 mm was accurate enough to determine susceptibility of carbapenem-resistant A. baumannii topolymyxin B. Polymyxin B can be an alternative to or more preferable than colistin for therapy ofcarbapenem-resistant A. baumannii infections.


Assuntos
Acinetobacter baumannii/efeitos dos fármacos , Antibacterianos/farmacologia , Polimixina B/farmacologia , Carbapenêmicos/farmacologia , Farmacorresistência Bacteriana , Humanos , Técnicas In Vitro , Testes de Sensibilidade Microbiana
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...